A Phase 4 interventional study of Pramipexole and Methylphenidate in Major Depressive Disorder, Depression and Depressive Disorder, Major, sponsored by University of California, San Francisco. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Depressive Disorder, Major by University of California, San Francisco — 5 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Major · University of California, San Francisco.
Among the 17 studies in Depressive Disorder, Major by University of California, San Francisco, this one is the 4th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 4, and was the 15th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 17 studies in Depressive Disorder, Major by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 55 across the 16 interventional studies, 6 across the 1 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
2 of the studies in Depressive Disorder, Major by University of California, San Francisco that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896343University of California, San FranciscoUnderstanding the Neural Underpinnings of Risk-Taking Behavior in Psychiatric Disease | 2027-06 |
| NCT04581902University of California, San FranciscoBiomarkers of Depression and Treatment Response | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Depressive Disorder, Major by University of California, San Francisco, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess whether phenotyping-guided intervention selection is superior to intervention selection without phenotyping guidance (i.e., routine clinician and patient judgment regarding treatment selection) for depression.
This study will classify patients seen in the Depression Clinic of the UCSF Department of Psychiatry and Behavioral Sciences into one of five phenotypes (subtypes), including: 1) Anhedonia, 2) Cognitive deficits, 3) Stress sensitivity, 4) Anxious distress, and 5) Grief.
After phenotyping, participants will be randomized to receive phenotype-specific intervention (PSI) or care as usual (CAU).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pramipexole
Other: Care as usual (CAU) plan
Drug: Methylphenidate
Other: Care as usual (CAU) plan
Behavioral: Mindfulness-based Stress Sensitivity Therapy (MBSST)
Other: Care as usual (CAU) plan
Drug: Phenelzine
Other: Care as usual (CAU) plan
Behavioral: Complicated Grief Treatment (CGT)
Other: Care as usual (CAU) plan
CAU plan modified to include a trial of pramipexole.
CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.
CAU plan modified to include a trial of CGT.
Unmodified CAU plan.
Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) score
Within-phenotype and across-phenotype contrasts.
Time frame: Up to 24 weeks after randomization.
Snaith-Hamilton Pleasure Scale (SHAPS) score
For anhedonia phenotype only.
Time frame: Up to 24 weeks after randomization.
Clinically Useful Depression Outcome Scale Anxious Distress Specifier Subscale (CUDOS-A) score
For anxious distress phenotype only.
Time frame: Up to 24 weeks after randomization.
Generalized Anxiety Disorder 7-item (GAD-7) score
For anxious distress phenotype only.
Time frame: Up to 24 weeks after randomization.
Inventory of Complicated Grief (ICG) score
For grief phenotype only.
Time frame: Up to 24 weeks after randomization.
Perceived Deficits Questionnaire - Depression (PDQ-D) score
For cognitive deficits phenotype only.
Time frame: Up to 24 weeks after randomization.
Patient Health Questionnaire - 8 (PHQ-8) score
Within-phenotype and across-phenotype contrasts.
Time frame: Up to 24 weeks after randomization.
WHO Disability Assessment Schedule (WHODAS 2.0)
Within-phenotype and across-phenotype contrasts.
Time frame: Up to 24 weeks after randomization.
Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) response
50% reduction from baseline score. Within-phenotype and across-phenotype contrasts.
Time frame: Up to 24 weeks after randomization.
Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) remission
Score \< 6. Within-phenotype and across-phenotype contrasts.
Time frame: Up to 24 weeks after randomization.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Sep 2029, 57 months after the start.
Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 57 months is above that.
Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pramipexole · Methylphenidate · Phenelzine
University of California, San Francisco →